New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

about

A novel microtubule-modulating agent induces mitochondrially driven caspase-dependent apoptosis via mitotic checkpoint activation in human prostate cancer cells.

P2860

Q33905704-28001454-BC58-4A4A-9309-8ABD2732DFB4

P2860

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

Item

http://www.wikidata.org/entity/Q36066144

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

@ast

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

@en

type

Item

label

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

@ast

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

@en

prefLabel

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

@ast

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

@en

P1476

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

@en

P2093

Gian Luigi Cetto

http://www.w3.org/2001/XMLSchema#string

Teodoro Sava

http://www.w3.org/2001/XMLSchema#string

P2860

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Cancer statistics, 2004

Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.

A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: A Southwest Oncology Group trial (SWOG 9407).

Estramustine in combination with vinblastine and mitomycin-C for patients with progressive androgen independent adenocarcinoma of the prostate.

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group.

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study.

P304

53-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.5.1.53

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio B. Porcaro

Umberto Basso

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15757438

http://www.w3.org/2001/XMLSchema#string

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

about

P2860

P2860

New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698